Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares rose 4.1% on Wednesday . The stock traded as high as $2.11 and last traded at $2.05. Approximately 184,975 shares were traded during trading, a decline of 70% from the average daily volume of 620,672 shares. The stock had previously closed at $1.97.
Cortexyme Stock Down 0.5 %
The company has a market capitalization of $61.21 million, a PE ratio of -0.68 and a beta of 1.40. The company’s 50 day moving average is $1.50 and its two-hundred day moving average is $1.00.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Articles
- Five stocks we like better than Cortexyme
- Bank Stocks – Best Bank Stocks to Invest In
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Stock Splits, Do They Really Impact Investors?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
